

## AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method for producing an anti-tumor response in a mammalian subject, said method comprising:

isolating proliferating dendritic cells from bone marrow, lymph or blood, or, preparing said proliferating dendritic cells by differentiating in vitro precursors isolated from bone marrow, lymph or blood;

fusing the dendritic cells with tumor cells to form dendritic cell/tumor cell hybrids; and

administering to said subject a plurality of said dendritic cell/tumor cell hybrids, wherein said dendritic cell is not a T-lymphocyte, — or — B-lymphocyte, ~~monocyte/macrophage or another non-dendritic cell present in enriched or purified dendritic cell preparations.~~

2-4. (Cancelled)

5. (Previously presented) The method of Claim 1 wherein the plurality of hybrids is further induced to express the dendritic cell characteristics before using said hybrids for the production of an anti-tumor response.

6. (Cancelled)

7. (Previously presented) The method of Claim 5 wherein said dendritic cell characteristics are chosen from the group consisting of dendritic cell morphology, dendritic cell surface markers or dendritic cell activation markers and immune cell activation properties *in vitro*.

8. (Cancelled)

9. (Previously presented) The method of Claim 5 wherein said induction is performed using GM-CSF.

10. (Cancelled)

11. (Previously presented) The method of Claim 1 wherein the plurality of hybrids is treated to prevent proliferation before using said hybrids for the production of an anti-tumor response.

12. (Cancelled)

13. (Previously presented) The method of Claim 11 wherein said treatment occurs by irradiation.

14. (Cancelled)

15. (Previously presented) The method of Claim 1 wherein said plurality of hybrids is administered by injection.

16. (Cancelled)

17. (Previously presented) The method of Claim 15 wherein said injection is carried out parenterally.

18-20. (Cancelled)

21. (Previously presented) The method of Claim 1 wherein said dendritic cell is of myeloid origin.

22. (Cancelled)

23. (Previously presented) The method of Claim 1 wherein said dendritic cell is of lymphoid origin.

24-28. (Cancelled)

29. (Previously presented) The method of Claim 1 wherein the dendritic cell and/or the tumor cell is human in origin.

30-37. (Cancelled)

38. (Currently amended) The method of ~~claim 31~~claim 1, wherein said dendritic cells are prepared~~proliferation is induced~~ by culturing ~~DC~~said precursors in the presence of cytokines so as to induce differentiation.

39-50. (Cancelled)

51. (New) The method of claim 1, wherein the dendritic cells are isolated from bone marrow, lymph, or blood obtained from the mammalian subject in need of treatment.

Appl. No. : 09/802,397  
Filed : March 9, 2001

52. (New) The method of claim 1, further comprising selecting the dendritic cell /tumor cell hybrids to obtain a dendritic cell/ tumor cell hybridoma, wherein the dendritic cell/tumor cell hybridoma is administered to said subject.

## SUMMARY OF INTERVIEW

### Exhibits and/or Demonstrations

Inventor presented exhibit with data.

### Identification of Claims Discussed

all pending

### Identification of Prior Art Discussed

Guo, et al.

Sornasse, et al.

### Proposed Amendments

Amendment to claim 1 was presented which recited that DC are isolated from "bone marrow or blood" and that DC are "proliferating."

### Principal Arguments and Other Matters

Declaration will be submitted based upon materials presented in the exhibit to show that DC isolated from sources of proliferating DCs efficiently produce DC/tumor cell hybrids and that fused cells were not generated very well from non-proliferating sources such as spleen.

### Results of Interview

Applicants will prepare response which includes proposed amendments and Declaration based upon data discussed at the interview.